DLA PIPER LLP (US)

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association of innovative biopharmaceutical research companies.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $60,000.00 income · posted Jul 21, 2025

Bills named in this filing 2

S 832
EPIC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 6

Pharmacy

Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and prices.

Health Issues

S. 832, EPIC Act of 2025.

Medicare/Medicaid

Medicare policies.

Budget/Appropriations

H.R. 1, One Big Beautiful Bill Act, provisions impacting pharmaceuticals.

Defense

National security issues related to pharmaceutical industry, including supply chain.

Trade (domestic/foreign)

Trade policies and agreements, including IP protections, and administrative tariff actions.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.